Patent ID: 7754201

Claim:
A method for producing an immune response of a host to infection of a first and a second pathogenic virus, comprising: administering to the host a first recombinant adenovirus comprising a first antigen sequence heterologous to native adenovirus and encoding a first viral antigen from the first pathogenic virus, expression of the first viral antigen by the first recombinant adenovirus eliciting an immune response directed against the first viral antigen in a host upon infection of the host by the first recombinant adenovirus; administering to the host a second recombinant adenovirus comprising a second antigen sequence heterologous to native adenovirus and encoding a second viral antigen from the second pathogenic virus, expression of the second viral antigen by the second recombinant adenovirus eliciting an immune response directed against the second viral antigen in a host upon infection of the host by the second recombinant adenovirus, wherein adenoviral backbones of the first and the second recombinant adenoviruses are of the same serotype selected from the group consisting of adenovirus serotype 1-51, wherein either an entire or a part of the fiber region comprising either one of knob, shaft, penton base domain of the fiber region or a combination thereof, of the second recombinant adenovirus is of a serotype that is different from the serotype of fiber region of the first recombinant adenovirus and wherein the first or second recombinant adenovirus further comprises an immuno-stimulator sequence that is heterologous to native adenovirus and encodes an immuno-stimulator such that the immune response elicited by the first and second recombinant adenovirus generates an antibody directed against the first viral antigen, the second viral antigen or a combination thereof wherein the first and the second pathogenic viral antigen are inserted into E1, E3 or E4 region of the first and the second adenovirus vectors, and wherein the immune-stimulatory sequence is inserted into E4, E3 or E1 region of the first and the second adenovirus vectors, in which region does not contain the first and/or the second pathogenic virus antigen; isolating the antibody generated after said administration of the first and the second recombinant adenovirus; and administering the antibody to the host or to another host, thereby producing the immune response of the host to infection of the first and the second pathogenic virus.